Can a new form of radiation shrink large chest tumors?
NCT ID NCT07744074
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This trial is testing a new type of radiation therapy called carbon-ion lattice radiotherapy for people with large chest tumors that have not responded to standard treatments. The study aims to find the highest safe dose and to see if the treatment can help control the disease. Researchers will also collect blood, urine, and stool samples to look for markers that might predict how well a person responds to the therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Carbon-ion lattice radiotherapy
- What this could lead to
- If successful, this could offer a new treatment option for people with large chest tumors that have not responded to standard therapies, potentially improving local control and survival.
- What could go wrong
- This is an early-phase trial with only 12 participants, so results may not apply broadly. The treatment may cause side effects, and its effectiveness is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 12 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age ≥ 18 years old; 2. Pathologically confirmed thoracic solid malignant tumors; 3. Local recurrence or failure of prior standard therapies (including surgery, radiotherapy, systemic therapy, etc.), deemed unsuitable for or lacking standard treatment options following Multidisciplinary Team (MDT) evaluation, and planned to receive heavy-ion radiotherapy； 4. Maximum diameter of the target lesion ≥ 4.5 cm; 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; 6. Life expectancy ≥ 6 months; 7. Signed informed consent. Exclusion Criteria: 1. Tumors adjacent to critical organs at risk (OARs) where dose constraints cannot be met through plan optimization; 2. Prior radiotherapy to the intended treatment area, where re-irradiation would fail to meet normal tissue dose constraints; 3. Presence of recognized standard treatment options for which the patient is eligible (e.g., radical surgery, concurrent chemoradiotherapy, or standard systemic therapy); 4. Primary hematologic malignancies; 5. Uncontrolled severe comorbidities, including active infections, unstable cardiovascular or cerebrovascular diseases, and severe hepatic or renal insufficiency; 6. Other diseases deemed by the investigator to compromise patient safety; 7. Psychiatric disorders or cognitive impairment that would prevent cooperation with treatment; 8. Pregnancy or lactation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Carbon ion radiotheray are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310000, China